The healthcare sector is having its market moment. How to find the Best Stocks in the space

Healthcare has staged a notable short‑term rotation, outpacing the S&P 500 by 5.7% over a three‑day stretch (the most since 2008) and showing 66% of names above their 20‑day moving average versus 25% for tech, suggesting strengthening leadership beneath the market surface rather than a confirmed regime change. Eli Lilly is the standout breakout—new highs after Q3 revenue grew 54% with Mounjaro and Zepbound up 109% and 184% y/y respectively and multiple analyst upgrades—while AbbVie (+36% over the past year) and Amgen (+12%) are also advancing, with AbbVie backed by analysts’ ~34% EPS growth expectations and margin‑expansion plans and Amgen ramping R&D (+31% y/y) and embedding AI across discovery and manufacturing. The piece frames these rallies as fundamentally supported but advises disciplined entries and risk management—buying on pullbacks to technical support (Lilly’s $950–$960 consolidation area, AbbVie’s rising 200‑day as a rolling stop, Amgen defending the $320s) rather than chasing overbought moves.

Analysis

Healthcare has registered a pronounced short-term rotation versus the S&P 500, outpacing the index by 5.7% over a three-day stretch—the most relative strength since 2008—and showing 66% of its constituents above their 20-day moving averages versus 25% for tech, indicating strengthening breadth within the sector rather than an immediate regime shift. Energy shows even stronger short-term technicals with 100% above the 20-day, underscoring that the move is pattern- and momentum-driven across select value-oriented groups.

Eli Lilly (LLY) is the clear breakout: Q3 revenue rose 54% year-over-year with Mounjaro and Zepbound posting +109% and +184% respectively, and the stock received four analyst upgrades and two reaffirms ahead of a breakout past spring 2025 highs. AbbVie (ABBV) has returned 36% over the past year, carries a roughly $400 billion market cap and a 3% dividend yield, and benefits from analyst expectations of ~34% EPS growth and management-led margin expansion via SG&A reductions. Amgen (AMGN) posted a breakout on Q3 strength while increasing R&D spending 31% y/y and prioritizing AI across discovery and manufacturing, though its RSI sits in the mid-70s suggesting near-term cooling risk.

Tactical risk management is emphasized: the commentary recommends buying on validated pullbacks rather than chasing overbought moves—key technical reference points include LLY’s $950–$960 consolidation support, AbbVie’s rising 200-day as a rolling stop (implying ~13% downside), and Amgen defending the low-$320s breakout area—while investors should monitor sector breadth and execution on earnings and R&D catalysts to confirm sustainability.

Key Decisions for Investors

• Consider initiating or adding to Eli Lilly on weakness toward the $950–$960 consolidation area rather than buying at the immediate breakout given the 54% y/y revenue growth and strong drug sales
• Position AbbVie as a core large-cap healthcare holding given its 36% trailing year return, analyst-driven ~34% EPS growth expectations and 3% yield, using the rising 200-day as a rolling stop (~13% downside)
• For Amgen, wait for a short cooling period or a pullback toward the low-$320s before adding exposure, supported by its 31% y/y R&D increase and AI-driven pipeline investments
• Monitor sector breadth metrics (percent above 20-day MA) and analyst revisions for signs the healthcare rotation is structurally sustainable before meaningfully increasing sector weights